pharma · Familial adenomatous polyposis (FAP) · Familial Adenomatous Polyposis · BDRX
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals is a pharma organization headquartered in cardiff, GB. It trades on NYSE under ticker BDRX. Primary therapeutic focus areas include Familial adenomatous polyposis (FAP), Familial Adenomatous Polyp
cardiff, GB HQ
2000 Founded
25 Employees
Public company Type
BDRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- cardiff, GB
- Founded
- 2000
- Employees
- 25
- Programs
- 4
- Drugs
- 5
- Patents
- 2
MTX110
Phase 1 · small molecule · Recurrent Glioblastoma
MTX110 for Recurrent Glioblastoma is a Phase 1 program (small_molecule) at Biodexa Pharmaceuticals Plc with 1 ClinicalTrials.gov record(s).
Internal code MTX110-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Biodexa Pharmaceuticals Plc
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Recurrent Glioblastoma
- Status
- terminated
- Trials
- 1